MET and non-small cell lung carcinoma: ,56,57 For solid tumors, dual-targeting of EGFR and cellular mesenchymal epithelial transition factor (c-MET) with a bispecific antibody, amivantamab, is approved for treatment of patients with non-small cell lung cancer (NSCLC) with an exon 20 insertion in the EGFR gene.58